Val103Ile polymorphism of the melanocortin-4 receptor gene (MC4R) in cancer cachexia

BMC Cancer

Table 4 Change of appetite and cachexia status (as defined in Methods) and MC4R 103Ile allele carrier status

Patients with	Total N¹ = 499 [N = 479]	Cachexia N = 105 *(21.1)* [N = 100]	No cachexia N = 394 *(78.9)* [N = 379]	Heterozygotes for the 103Ile- allele N = 24 *(4.8)* [N = 22]	Homozygotes for the Val103-allele N = 475 *(95.2)* [N = 457]
Loss of appetite:	232 *(46.5)* [223]	71 *(67.6)* [69]	161 *(40.9)* [154]	9 *(37.5)* [8]	223 *(46.9)* [215]
General, not further specified	95 (19) [91]	37 (35.2) [36]	58 (14.7) [55]	4 (16.7) [3]	91 (19.1) [88]
Prior to initiation of therapy	22 (4.4) [21]	14 (13.3) [14]	8 (2.1) [7]	2 (8.3) [2]	20 (4.2) [19]
During therapy	115 (23.1) [111]	20 (19.1) [19]	95 (24.1) [92]	3 (12.5) [3]	112 (23.6) [108]
Occurrence of both food craving and revulsion	18 *(3.6)* [18]	2 *(1.9)* [2]	16 *(4)* [16]	1 *(4.2)* [1]	17 *(3.6)* [17]
Increase of appetite/no change	249 *(49.9)* [238]	32 *(30.5)* [29]	217 *(55.1)* [209]	14 *(58.3)* [13]	235 *(49.5)* [225]

¹N = 499 [479]: Of the 509 patients ten without information were excluded, because the patients did not give any information or could not remember their appetite.
Numbers in square brackets denote the number of patients without early leucaemic preliminary stages.
Numbers in parentheses denote the particular percentage.

ISSN: 1471-2407